Bengt Ågerup executive chairman of the Board of Q-Med
BENGT ÅGERUP EXECUTIVE CHAIRMAN OF THE BOARD OF Q-MED * Bengt Ågerup was appointed new chairman of the Board at a meeting of the Q-Med Board today. * Q-Med's former chairman of the Board Robert Wikholm will continue as a member of the Board. Q-Med was founded by Bengt Ågerup, who also invented the technology which is the foundation of all of Q-Med's business operations today, the NASHA technology (Non-Animal Stabilized Hyaluronic Acid). Bengt Ågerup has worked for many years as a researcher, amongst other things at Pharmacia. Up until April 1999 he was Q-Med's President and CEO and after that he worked as the Head of Research and Production. Bengt Ågerup will now go on to act as the executive chairman of the Board of Q-Med. As before he will devote a great deal of time to Q-Med's explorative business activities: finding new projects, working with the American biotechnology company Ixion where Q-Med has the majority shareholding etc. "It has always been my ambition to develop Q-Med into a company that can function through its own efforts and on its own merits. Today Q-Med has at its disposal competent personnel throughout the organization who can implement the business plan with vigour. In the phase of strong growth that the company is now in, I can from Paris where I reside work more effectively in a freer role as executive chairman of the Board. My strong commitment to the company is also demonstrated by the fact that I intend to keep my shareholding in the company", says Bengt Ågerup. December 19, 2000 Uppsala, Sweden Q-Med AB (publ) Per Olof Wallström, President and CEO Queries should be addressed to Per Olof Wallström, President and CEO, on +46(0)18-474 90 00 or +46(0)70-974 90 70. Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. All products are based on the company's patented technology for the production of NASHA - Non-Animal Stabilized Hyaluronic Acid. Q-Med's operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation. The products RESTYLANE, RESTYLANE Fine Lines and PERLANE are used for the filling out of lips and facial wrinkles and today account for the majority of sales. The development of MACROLANE for breast augmentation is ongoing. DUROLANE, Q-Med's product for the treatment of osteoarthritis in the knee-joint, is in the clinical documentation phase. DEFLUX is a product which has been approved in Europe for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children and stress urinary incontinence in women. Since July 2000 Q-Med has held a majority interest in the American biotechnology company Ixion Biotechnology, Inc., which carries out research within cell therapy for diabetes. Q-Med today has 195 employees, with 140 at the company's production facility and head office in Uppsala, 15 at Ixion and the remainder in wholly owned foreign subsidiaries. The Q-Med share has been listed on the O-list of the OM Stockholm Stock Exchange since December 1999. Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Home page: www.q-med.com ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/12/19/20001219BIT00940/bit0001.doc http://www.bit.se/bitonline/2000/12/19/20001219BIT00940/bit0002.pdf